"Doudna's Aclaris CEO Steps Down, Secures $114M Liver Disorder Deal with Genevant"
Jennifer Doudna's lab published a study detailing how antibody fragments can target virus-like particles with gene editing machinery to T cells, co-founding genetic medicine delivery startup Azalea Therapeutics, which has raised $10 million.